Jazz Pharmaceuticals (JAZZ) Bank of America 2025 Healthcare Conference summary

Financial and operational highlights

• Q1 revenue reached $898 million, driven by strong neuroscience product growth, especially Xywav and Epidiolex, despite seasonality and inventory drawdown impacts.

• Oncology revenue declined 11% year-over-year, mainly due to fewer shipping weeks and competitive pressures, but normalization is expected in subsequent quarters.

• Acquisition of Chimerix closed in April, adding dordaviprone for H3 K27M-mutant diffuse midline glioma, with a PDUFA date in August and potential rapid launch if approved.

• Confirmed top-line revenue guidance for the year, with only modest tweaks and a slight reduction in R&D due to early study readouts.

• Strong financial position maintained post-acquisition, supporting ongoing investment in marketed products, pipeline advancement, and further corporate development.

Product pipeline and clinical development

• ZEPZELCA phase III data in 1st line maintenance to be presented at ASCO, with FDA submission already made and guideline inclusion sought.

• Zanidatamab received CHMP recommendation for 2nd line BTC in Europe; phase II GEA data to be updated at ASCO, with phase III readout expected in 2H 2025.

• Pan-tumor study for zanidatamab includes three cohorts, with a single anticipated data update; $2 billion peak sales estimate includes BTC, GEA, pan-tumor, and metastatic breast cancer.

• No FDA review disruptions reported for ZEPZELCA or dordaviprone; both remain on track for their respective PDUFA dates.

• Ongoing review of clinical trial protocols, especially for dordaviprone, to ensure optimal design and powering for success.

Market dynamics and competitive landscape

• Xywav continues to add patients in both narcolepsy and idiopathic hypersomnia, maintaining strong positioning as the only low sodium oxybate.

• True generics for Xyrem expected by 2026, with Hikma able to enter earlier; impact on Xywav uncertain but differentiation based on sodium content emphasized.

• Orexin therapies seen as complementary rather than competitive to oxybate, as they primarily address daytime wakefulness without improving nighttime sleep quality.

• Tariff risks on imported pharmaceuticals are being monitored, with mitigation strategies in place to minimize financial impact through 2025.

• Ongoing legal settlements and the Chimerix acquisition contributed to some Q1 operational complexity.